One year of abaloparatide, a selective peptide activator of the PTH1 receptor, increased bone mass and strength in ovariectomized rats.

Varela A, Chouinard L, Lesage E, Guldberg R, Smith SY, Kostenuik PJ, Hattersley G

Bone25 Nov 2016Cited by 36 (Europe PMC)

PMID27894941DOI10.1016/j.bone.2016.11.027PepBankPUB-27894941

Publisher page PubMedAsk about this study

Summary

Abaloparatide is a novel 34 amino acid peptide selected to be a potent and selective activator of the parathyroid hormone receptor 1 (PTHR1) signaling pathway. The effects of 12months of abaloparatide treatment on bone mass, bone strength and bone quality was assessed in osteopenic ovariectomized (OVX) rats. SD rats were subjected to OVX or sham surgery at 6months of age and left untreated for 3months to allow OVX-induced bone loss. Eighteen OVX rats were sacrificed after this bone depletion period, and the remaining OVX rats received daily s.c. injections of vehicle (n=18) or abaloparatide at 1, 5 or 25μg/kg/d (n=18/dose level) for 12months. Sham controls (n=18) received vehicle daily. Bone changes were assessed by DXA and pQCT after 0, 3, 6 or 12months of treatment, and destructive biomechanical testing was conducted at month 12 to assess bone strength and bone quality. Abaloparatide dose-dependently increased bone mass at the lumbar spine and at the proximal and diaphyseal regions of the tibia and femur. pQCT revealed that increased cortical bone volume at the tibia was a result of periosteal expansion and endocortical bone apposition. Abaloparatide dose-dependently increased structural strength of L4-L5 vertebral bodies, the femur diaphysis, and the femur neck. Increments in peak load for lumbar spine and the femur diaphysis of abaloparatide-treated rats persisted even after adjusting for treatment-related increments in BMC, and estimated material properties were maintained or increased at the femur diaphysis with abaloparatide. The abaloparatide groups also exhibited significant and positive correlations between bone mass and bone strength at these sites. These data indicate that gains in cortical and trabecular bone mass with abaloparatide are accompanied by and correlated with improvements in bone strength, resulting in maintenance or improvement in bone quality. Thus, this study demonstrated that long-term daily administration of abaloparatide to osteopenic OVX rats led to dose-dependent improvements in bone mass, geometry and strength.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study15

15 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide dose-dependently increased lumbar spine bone mass.
In plain wordsIn rats, abaloparatide increased lumbar spine bone mass with increasing dose compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseLumbar spine bone mass
Study
ratn: not reported in source
osteopenic ovariectomized SD rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1, 5 or 25μg/kg/d · subcutaneous · 12 monthsAs given in this study (rat).
Source sentences
Summary
Abaloparatide dose-dependently increased bone mass at the lumbar spine and at the proximal and diaphyseal regions of the tibia and femur.
1 context sentence(design, population, supporting numbers)
Summary · context
Eighteen OVX rats were sacrificed after this bone depletion period, and the remaining OVX rats received daily s.c. injections of vehicle (n=18) or abaloparatide at 1, 5 or 25μg/kg/d (n=18/dose level) for 12months.
Show in the study text Report a problemFND-2789494101
02AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide dose-dependently increased proximal tibial bone mass.
In plain wordsIn rats, abaloparatide increased proximal tibial bone mass with increasing dose compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseProximal tibial bone mass
Study
ratn: not reported in source
osteopenic ovariectomized SD rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1, 5 or 25μg/kg/d · subcutaneous · 12 monthsAs given in this study (rat).
Source sentences
Summary
Abaloparatide dose-dependently increased bone mass at the lumbar spine and at the proximal and diaphyseal regions of the tibia and femur.
1 context sentence(design, population, supporting numbers)
Summary · context
Eighteen OVX rats were sacrificed after this bone depletion period, and the remaining OVX rats received daily s.c. injections of vehicle (n=18) or abaloparatide at 1, 5 or 25μg/kg/d (n=18/dose level) for 12months.
Show in the study text Report a problemFND-2789494102
03AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide dose-dependently increased tibial diaphysis bone mass.
In plain wordsIn rats, abaloparatide increased tibial shaft bone mass with increasing dose compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTibial diaphysis bone mass
Study
ratn: not reported in source
osteopenic ovariectomized SD rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1, 5 or 25μg/kg/d · subcutaneous · 12 monthsAs given in this study (rat).
Source sentences
Summary
Abaloparatide dose-dependently increased bone mass at the lumbar spine and at the proximal and diaphyseal regions of the tibia and femur.
1 context sentence(design, population, supporting numbers)
Summary · context
Eighteen OVX rats were sacrificed after this bone depletion period, and the remaining OVX rats received daily s.c. injections of vehicle (n=18) or abaloparatide at 1, 5 or 25μg/kg/d (n=18/dose level) for 12months.
Show in the study text Report a problemFND-2789494103
04AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide dose-dependently increased proximal femoral bone mass.
In plain wordsIn rats, abaloparatide increased proximal femoral bone mass with increasing dose compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseProximal femoral bone mass
Study
ratn: not reported in source
osteopenic ovariectomized SD rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1, 5 or 25μg/kg/d · subcutaneous · 12 monthsAs given in this study (rat).
Source sentences
Summary
Abaloparatide dose-dependently increased bone mass at the lumbar spine and at the proximal and diaphyseal regions of the tibia and femur.
1 context sentence(design, population, supporting numbers)
Summary · context
Eighteen OVX rats were sacrificed after this bone depletion period, and the remaining OVX rats received daily s.c. injections of vehicle (n=18) or abaloparatide at 1, 5 or 25μg/kg/d (n=18/dose level) for 12months.
Show in the study text Report a problemFND-2789494104
05AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide dose-dependently increased femoral diaphysis bone mass.
In plain wordsIn rats, abaloparatide increased femoral shaft bone mass with increasing dose compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseFemoral diaphysis bone mass
Study
ratn: not reported in source
osteopenic ovariectomized SD rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1, 5 or 25μg/kg/d · subcutaneous · 12 monthsAs given in this study (rat).
Source sentences
Summary
Abaloparatide dose-dependently increased bone mass at the lumbar spine and at the proximal and diaphyseal regions of the tibia and femur.
1 context sentence(design, population, supporting numbers)
Summary · context
Eighteen OVX rats were sacrificed after this bone depletion period, and the remaining OVX rats received daily s.c. injections of vehicle (n=18) or abaloparatide at 1, 5 or 25μg/kg/d (n=18/dose level) for 12months.
Show in the study text Report a problemFND-2789494105
06AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide increased tibial cortical bone volume.
In plain wordsIn rats, abaloparatide increased tibial cortical bone volume compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTibial cortical bone volume
Study
ratn: not reported in source
osteopenic ovariectomized SD rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1, 5 or 25μg/kg/d · subcutaneous · 12 monthsAs given in this study (rat).
Source sentences
Summary
pQCT revealed that increased cortical bone volume at the tibia was a result of periosteal expansion and endocortical bone apposition.
1 context sentence(design, population, supporting numbers)
Summary · context
Eighteen OVX rats were sacrificed after this bone depletion period, and the remaining OVX rats received daily s.c. injections of vehicle (n=18) or abaloparatide at 1, 5 or 25μg/kg/d (n=18/dose level) for 12months.
Show in the study text Report a problemFND-2789494106
07AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide dose-dependently increased vertebral body structural strength.
In plain wordsIn rats, abaloparatide increased vertebral strength with increasing dose compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseVertebral structural strength
Study
ratn: not reported in source
osteopenic ovariectomized SD rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1, 5 or 25μg/kg/d · subcutaneous · 12 monthsAs given in this study (rat).
Source sentences
Summary
Abaloparatide dose-dependently increased structural strength of L4-L5 vertebral bodies, the femur diaphysis, and the femur neck.
1 context sentence(design, population, supporting numbers)
Summary · context
Eighteen OVX rats were sacrificed after this bone depletion period, and the remaining OVX rats received daily s.c. injections of vehicle (n=18) or abaloparatide at 1, 5 or 25μg/kg/d (n=18/dose level) for 12months.
Show in the study text Report a problemFND-2789494107
08AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide dose-dependently increased femoral diaphysis structural strength.
In plain wordsIn rats, abaloparatide increased femoral shaft strength with increasing dose compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseFemoral diaphysis structural strength
Study
ratn: not reported in source
osteopenic ovariectomized SD rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1, 5 or 25μg/kg/d · subcutaneous · 12 monthsAs given in this study (rat).
Source sentences
Summary
Abaloparatide dose-dependently increased structural strength of L4-L5 vertebral bodies, the femur diaphysis, and the femur neck.
1 context sentence(design, population, supporting numbers)
Summary · context
Eighteen OVX rats were sacrificed after this bone depletion period, and the remaining OVX rats received daily s.c. injections of vehicle (n=18) or abaloparatide at 1, 5 or 25μg/kg/d (n=18/dose level) for 12months.
Show in the study text Report a problemFND-2789494108
09AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide dose-dependently increased femoral neck structural strength.
In plain wordsIn rats, abaloparatide increased femoral neck strength with increasing dose compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseFemoral neck structural strength
Study
ratn: not reported in source
osteopenic ovariectomized SD rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1, 5 or 25μg/kg/d · subcutaneous · 12 monthsAs given in this study (rat).
Source sentences
Summary
Abaloparatide dose-dependently increased structural strength of L4-L5 vertebral bodies, the femur diaphysis, and the femur neck.
1 context sentence(design, population, supporting numbers)
Summary · context
Eighteen OVX rats were sacrificed after this bone depletion period, and the remaining OVX rats received daily s.c. injections of vehicle (n=18) or abaloparatide at 1, 5 or 25μg/kg/d (n=18/dose level) for 12months.
Show in the study text Report a problemFND-2789494109
10AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, lumbar spine peak-load increases with abaloparatide persisted after adjustment for bone mineral content increases.
In plain wordsIn rats, lumbar spine load capacity increased with abaloparatide even after adjustment for bone mineral content compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseBMC-adjusted lumbar peak load
Study
ratn: not reported in source
osteopenic ovariectomized SD rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1, 5 or 25μg/kg/d · subcutaneous · 12 monthsAs given in this study (rat).
Source sentences
Summary
Increments in peak load for lumbar spine and the femur diaphysis of abaloparatide-treated rats persisted even after adjusting for treatment-related increments in BMC,
1 context sentence(design, population, supporting numbers)
Summary · context
Eighteen OVX rats were sacrificed after this bone depletion period, and the remaining OVX rats received daily s.c. injections of vehicle (n=18) or abaloparatide at 1, 5 or 25μg/kg/d (n=18/dose level) for 12months.
Show in the study text Report a problemFND-2789494110
11AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, femoral diaphysis peak-load increases with abaloparatide persisted after adjustment for bone mineral content increases.
In plain wordsIn rats, femoral shaft load capacity increased with abaloparatide even after adjustment for bone mineral content compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseBMC-adjusted femoral diaphysis peak load
Study
ratn: not reported in source
osteopenic ovariectomized SD rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1, 5 or 25μg/kg/d · subcutaneous · 12 monthsAs given in this study (rat).
Source sentences
Summary
Increments in peak load for lumbar spine and the femur diaphysis of abaloparatide-treated rats persisted even after adjusting for treatment-related increments in BMC,
1 context sentence(design, population, supporting numbers)
Summary · context
Eighteen OVX rats were sacrificed after this bone depletion period, and the remaining OVX rats received daily s.c. injections of vehicle (n=18) or abaloparatide at 1, 5 or 25μg/kg/d (n=18/dose level) for 12months.
Show in the study text Report a problemFND-2789494111
12AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, estimated femoral diaphysis material properties were maintained or increased with abaloparatide.
In plain wordsIn rats, abaloparatide maintained or increased estimated femoral shaft material properties compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
MixedFemoral diaphysis material properties
Study
ratn: not reported in source
osteopenic ovariectomized SD rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1, 5 or 25μg/kg/d · subcutaneous · 12 monthsAs given in this study (rat).
Source sentences
Summary
and estimated material properties were maintained or increased at the femur diaphysis with abaloparatide.
1 context sentence(design, population, supporting numbers)
Summary · context
Eighteen OVX rats were sacrificed after this bone depletion period, and the remaining OVX rats received daily s.c. injections of vehicle (n=18) or abaloparatide at 1, 5 or 25μg/kg/d (n=18/dose level) for 12months.
Show in the study text Report a problemFND-2789494112
13AnimalAnimal study (in vivo)Other
In abaloparatide-treated ovariectomized rats, bone mass correlated positively and significantly with bone strength at the measured sites.
In plain wordsIn rats receiving abaloparatide, greater bone mass was linked to greater bone strength.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseBone mass-strength correlation
Study
ratn: not reported in source
osteopenic ovariectomized SD rats
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1, 5 or 25μg/kg/d · subcutaneous · 12 monthsAs given in this study (rat).
Source sentences
Summary
The abaloparatide groups also exhibited significant and positive correlations between bone mass and bone strength at these sites.
2 context sentences(design, population, supporting numbers)
Summary · context
Abaloparatide dose-dependently increased structural strength of L4-L5 vertebral bodies, the femur diaphysis, and the femur neck.
Summary · context
Eighteen OVX rats were sacrificed after this bone depletion period, and the remaining OVX rats received daily s.c. injections of vehicle (n=18) or abaloparatide at 1, 5 or 25μg/kg/d (n=18/dose level) for 12months.
Show in the study text Report a problemFND-2789494113
14AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide-associated increases in tibial cortical bone volume resulted partly from periosteal expansion.
In plain wordsIn rats, outer tibial surface expansion contributed to increased cortical volume with abaloparatide compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTibial periosteal expansion
Study
ratn: not reported in source
osteopenic ovariectomized SD rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1, 5 or 25μg/kg/d · subcutaneous · 12 monthsAs given in this study (rat).
Source sentences
Summary
pQCT revealed that increased cortical bone volume at the tibia was a result of periosteal expansion and endocortical bone apposition.
1 context sentence(design, population, supporting numbers)
Summary · context
Eighteen OVX rats were sacrificed after this bone depletion period, and the remaining OVX rats received daily s.c. injections of vehicle (n=18) or abaloparatide at 1, 5 or 25μg/kg/d (n=18/dose level) for 12months.
Show in the study text Report a problemFND-2789494114
15AnimalAnimal study (in vivo)Efficacy outcome
In ovariectomized rats, abaloparatide-associated increases in tibial cortical bone volume resulted partly from endocortical bone apposition.
In plain wordsIn rats, inner tibial surface bone deposition contributed to increased cortical volume with abaloparatide compared with vehicle.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTibial endocortical bone apposition
Study
ratn: not reported in source
osteopenic ovariectomized SD rats
Comparator
vehicle
Outcome group
Bone and joint · Musculoskeletal
Studied dose
1, 5 or 25μg/kg/d · subcutaneous · 12 monthsAs given in this study (rat).
Source sentences
Summary
pQCT revealed that increased cortical bone volume at the tibia was a result of periosteal expansion and endocortical bone apposition.
1 context sentence(design, population, supporting numbers)
Summary · context
Eighteen OVX rats were sacrificed after this bone depletion period, and the remaining OVX rats received daily s.c. injections of vehicle (n=18) or abaloparatide at 1, 5 or 25μg/kg/d (n=18/dose level) for 12months.
Show in the study text Report a problemFND-2789494115

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.